CN115851682A - Creatine amidino hydrolase mutant with improved thermal stability - Google Patents
Creatine amidino hydrolase mutant with improved thermal stability Download PDFInfo
- Publication number
- CN115851682A CN115851682A CN202211447041.6A CN202211447041A CN115851682A CN 115851682 A CN115851682 A CN 115851682A CN 202211447041 A CN202211447041 A CN 202211447041A CN 115851682 A CN115851682 A CN 115851682A
- Authority
- CN
- China
- Prior art keywords
- mutant
- creatine
- thermal stability
- amino acid
- creatine amidinohydrolase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010077078 Creatinase Proteins 0.000 title claims abstract description 57
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 25
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- 241000894006 Bacteria Species 0.000 claims description 10
- 239000013612 plasmid Substances 0.000 claims description 7
- 241000588724 Escherichia coli Species 0.000 claims description 5
- 102220005459 rs36062788 Human genes 0.000 claims description 4
- 230000001580 bacterial effect Effects 0.000 claims description 3
- 244000063299 Bacillus subtilis Species 0.000 claims description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 2
- 230000002538 fungal effect Effects 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 abstract description 18
- 108090000790 Enzymes Proteins 0.000 abstract description 18
- 238000013461 design Methods 0.000 abstract description 3
- 230000009897 systematic effect Effects 0.000 abstract description 3
- 241000588986 Alcaligenes Species 0.000 abstract 1
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 24
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 14
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N 4-aminoantipyrine Chemical compound CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 description 12
- 229940109239 creatinine Drugs 0.000 description 12
- 238000000034 method Methods 0.000 description 11
- 230000035772 mutation Effects 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 10
- 229940024606 amino acid Drugs 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 8
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 8
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 6
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 238000012408 PCR amplification Methods 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 4
- 108010077895 Sarcosine Proteins 0.000 description 4
- 108010060059 Sarcosine Oxidase Proteins 0.000 description 4
- 102000008118 Sarcosine oxidase Human genes 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 229960003624 creatine Drugs 0.000 description 4
- 239000006046 creatine Substances 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 229940043230 sarcosine Drugs 0.000 description 4
- IRQRBVOQGUPTLG-UHFFFAOYSA-M sodium;3-(n-ethyl-3-methylanilino)-2-hydroxypropane-1-sulfonate Chemical compound [Na+].[O-]S(=O)(=O)CC(O)CN(CC)C1=CC=CC(C)=C1 IRQRBVOQGUPTLG-UHFFFAOYSA-M 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 238000006555 catalytic reaction Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006911 enzymatic reaction Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 238000012257 pre-denaturation Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 239000001715 Ammonium malate Substances 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 108010066906 Creatininase Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 102200012113 rs11466016 Human genes 0.000 description 1
- 102200069348 rs11538340 Human genes 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- ZPCAZHPYLUKSMY-UHFFFAOYSA-M sodium;3-(n-ethyl-3-methylanilino)-2-hydroxypropane-1-sulfonate;dihydrate Chemical compound O.O.[Na+].[O-]S(=O)(=O)CC(O)CN(CC)C1=CC=CC(C)=C1 ZPCAZHPYLUKSMY-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
- C12Y305/03003—Creatinase (3.5.3.3), i.e. creatine amidinohydrolase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/185—Escherichia
- C12R2001/19—Escherichia coli
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
The invention discloses a creatine amidinohydrolase mutant with improved thermal stability, belonging to the technical field of enzyme engineering. The invention obtains the mutant enzyme with obviously improved thermal stability by carrying out consensus design without systematic development prejudice on creatine amidino hydrolase from the alcaligenes. Compared with the wild type half-life period, the maximum half-life period of the optimally combined mutant is increased by 2841 times, which indicates that the stability of the mutant is obviously improved compared with the wild type.
Description
The present application is a divisional application of the following applications: application date: 8/28/2020; application No.: 202010886832.3; the invention provides a creatine amidinohydrolase mutant with improved thermal stability.
Technical Field
The invention belongs to the technical field of enzyme engineering, and particularly relates to a creatine amidinohydrolase mutant with improved thermal stability.
Background
Creatine amidinohydrolase is an essential enzyme for the enzymatic detection of creatinine content, which converts creatine into sarcosine and urea, further generating hydrogen peroxide that can be chemically detected. The enzyme is mainly derived from microorganisms and is widely applied to industries such as medical diagnosis, organic synthesis and the like at present.
Creatine amidinohydrolase is used in industrial determination of creatinine content and, in addition, is often used in clinical analyses for diagnosis of creatinine content in serum and urine and renal diseases different from that in healthy organisms. Creatinine is a final product of creatine phosphate metabolism applied to a human body, and enters urine from blood after being filtered by kidney, and is discharged out of the body. Generally, serum creatinine normally ranges between 35 and 150 μm, but when kidney function or muscle function is compromised, creatinine levels rise to 1000 μm and creatinine levels in blood and urine can reflect renal excretion. The most common methods for measuring creatinine content so far are Jaffe chemical detection and enzymatic colorimetric methods. In contrast, enzymatic assays are gaining attention due to their high sensitivity and selectivity. In the enzymatic detection method, a sample to be detected is continuously converted by virtue of creatinine hydrolase, creatine amidinohydrolase and sarcosine oxidase, finally creatinine is degraded into hydrogen peroxide, and the concentration of the hydrogen peroxide is determined by virtue of a colorimetric reaction under the catalysis of horseradish peroxidase, so that the aim of detecting the content of the creatinine is fulfilled.
Therefore, in order to better apply the creatine amidino hydrolase to clinical creatinine detection, the invention obtains creatine amidino hydrolase mutants with improved thermal stability by using a consensus design method, and the invention screens 21 amino acid mutation sites by using a consensus method without systematic developmental bias improved based on the traditional consensus method and performs site-specific mutation on the amino acid mutation sites to obtain the mutant enzymes with obviously improved thermal stability, thereby solving the problem that the existing creatine amidino hydrolase has poor thermal stability and cannot meet the requirements of being applied to reagents and laying a foundation for widening the industrial application of the creatine amidino hydrolase.
Disclosure of Invention
In order to better apply the creatine amidino hydrolase to clinical creatinine detection, the invention obtains creatine amidino hydrolase mutants with improved thermal stability by using a consensus design method, screens 21 amino acid mutation sites by using a consensus method which is improved based on a traditional consensus method and has no systematic developmental bias, and performs site-specific mutation on the amino acid mutation sites to obtain the mutant enzymes with obviously improved thermal stability, thereby solving the problem that the existing creatine amidino hydrolase has poor thermal stability and cannot meet the requirement of being applied to reagents, and laying a foundation for widening industrial application of the creatine amidino hydrolase.
The first purpose of the invention is to provide a creatine amidinohydrolase mutant, the amino acid sequence of which is shown in the following (a 1) or (a 2):
(a1) A derived protein which is obtained by substituting, deleting or adding one or more amino acids in the amino acid sequence shown in SEQ ID NO.1 and has the same function with the protein shown in SEQ ID NO. 1;
(a2) A derivative protein which is obtained by substituting one or more amino acid residues for one or more positions of the amino acid sequence shown in SEQ ID NO.1 and shows at least 92% homology with the protein shown in SEQ ID NO. 1.
Preferably, the creatine amidino hydrolase mutant has a mutation site of the amino acid sequence shown in SEQ ID NO.1, which comprises at least one of the following: 6 th, 17 th, 58 th, 108 th, 117 th, 165 th, 199 th, 251 th, 349 th and 351 th bits.
Further preferably, the creatine amidinohydrolase mutant comprises a single point mutant of any one of the single point mutation sites in the amino acid sequence shown in SEQ ID NO.1, L6P, D17V, G D, F108Y, T117P, Q165I, T199S, T251C, E53349 5364 zxft 53351E.
<xnotran> , , SEQ ID NO.1 L6P/D17 4984 zxft 4984 17V/G58 5272 zxft 5272 17V/T251 7945 zxft 7945 17V/K351 3272 zxft 3272 17V/T199 3424 zxft 3424 17V/F108 3535 zxft 3535 17V/Y109 3584 zxft 3584 17V/Q165 4284 zxft 4284 17V/E349 5325 zxft 5325 17V/T199S/T251 5623 zxft 5623 17V/F108Y/T199 6262 zxft 6262 17V/Y109F/T199 3256 zxft 3256 17V/T199S/K351 3456 zxft 3456 6P/D17V/T199 3838 zxft 3838 6P/D17V/T199S/K351 5749 zxft 5749 6P/D17V/F108Y/T199 6595 zxft 6595 17V/T199S/L6P/, L6P/D17V/Y109F/T199S/T251 6898 zxft 6898 6P/D17V/F108Y/T199S/K351 3428 zxft 3428 6P/D17V/Y109F/T199S/K351 3476 zxft 3476 6P/D17V/T199S/K351E/T251C . </xnotran>
It is a second object of the present invention to provide a gene encoding the creatine amidinohydrolase mutant.
In one embodiment of the invention, the gene comprises the nucleotide sequence of SEQ ID NO. 2.
The third purpose of the invention is to provide a vector containing the gene.
It is a fourth object of the invention to provide cells expressing said mutant.
In one embodiment of the invention, the cell is a fungal cell or a bacterial cell.
In one embodiment of the invention, the cell is Escherichia coli, yeast or Bacillus subtilis.
The fifth purpose of the invention is to provide 32 mutants for improving the thermal stability of creatine amidinohydrolase, which comprises the following steps:
1. searching the amino acid sequence of SEQ ID NO.1 in an NCBI database, deleting the repeated identical sequence, and selecting the amino acid sequence with the amino acid sequence consistency of more than 50 percent with the amino acid sequence of SEQ ID NO. 1;
2. then, performing multi-sequence comparison through ClustalX2.1 software, arranging the residual amino acid sequences into fasta files, introducing the fasta files into MEGA7.0 software, and constructing a Phylogenetic tree by utilizing an NJ algorithm in a Phylogenetic module of the MEGA7.0 software;
3. introducing weight according to the branch distance of a phylogenetic tree, calculating consensus sequence through a python script, and screening mutation sites related to thermal stability by combining a homologous modeling structure into L6P, D17V, P20T, V33L, C52N, G58D, W59F, D73T, F108Y, Y109F, T117P, L162A, V340L, Q165I, V362I, T199S, K166A, T251C, C331S, E349V and K351E.
In one embodiment of the invention, the mutant is a creatine amidinohydrolase with GenBank accession number BAA88830.1 mutated at the following sites:
(1) The 6 th leucine of the amino acid sequence shown in SEQ ID NO.1 is replaced by proline and is marked as L6P;
(2) The aspartic acid at the 17 th site of the amino acid sequence shown in SEQ ID NO.1 is replaced by valine, which is marked as D17V;
(3) The 58 th glycine of the amino acid sequence shown in SEQ ID NO.1 is replaced by aspartic acid and is marked as G58D;
(4) The 108 th phenylalanine of the amino acid sequence shown in SEQ ID NO.1 is substituted by tyrosine and is marked as F108Y;
(5) Threonine 117 of the amino acid sequence shown in SEQ ID NO.1 was substituted with proline and designated as T117P.
(6) The glutamine at position 165 of the amino acid sequence shown in SEQ ID NO.1 is substituted with isoleucine and is designated as Q165I.
(7) The amino acid sequence shown in SEQ ID NO.1 has the amino acid sequence in which threonine 199 is substituted with serine and designated T199S.
(8) The 251 st threonine of the amino acid sequence shown in SEQ ID NO.1 is substituted by cysteine and is denoted as T251C.
(9) The glutamic acid at position 349 of the amino acid sequence shown in SEQ ID NO.1 is substituted by valine and is marked as E349V.
(10) The 351 st lysine of the amino acid sequence shown in SEQ ID NO.1 is substituted by glutamic acid and is marked as K351E. The technical scheme of the invention has the following advantages:
1. the creatine amidinohydrolase mutant provided by the invention comprises a single-point mutant and a combined mutant, and compared with wild creatine amidinohydrolase (BAA 88830.1), the single-point mutant and the combined mutant have longer half-lives at 55 ℃ and 57 ℃; especially the combination mutant, showed the additive effect of single point mutant heat stability, and the half-life is about 2841 times of that of wild-type creatine amidinohydrolase (BAA 88830.1). Based on the above, the creatine amidinohydrolase mutant provided by the invention has better thermal stability, and the creatine amidinohydrolase mutant obtained by the construction method provided by the invention has excellent thermal stability and catalytic activity when catalyzing creatine to generate sarcosine and urea at higher temperature.
2. The constructed gene engineering bacterium of the creatine amidinohydrolase (BAA 88830.1) can efficiently express the creatine amidinohydrolase mutant, and has the advantages of simple culture condition, short culture period, convenient purification of expression products and the like.
Detailed Description
Mutant naming mode:
"amino acid substituted for the original amino acid position" is used to indicate the mutant. As with L6P, the amino acid at position 6 is replaced by Leu to Pro of the parent creatine amidinohydrolase, the numbering of the positions corresponding to the amino acid sequence of the parent creatine amidinohydrolase.
Example 1: construction of single-point creatine amidinohydrolase (BAA 88830.1) mutant
Wild-type creatine amidino hydrolase plasmid Pany1-CR-AF-WT was deposited in the laboratory, and single-site creatine amidino hydrolase mutants were constructed by the whole plasmid PCR method. The details are as follows: using Pany1-CR-AF-WT as a template, the primers upstream and downstream of each mutation site are shown in Table 1, and are named in the format of "substitution of amino acids by mutation sites", respectively. One round of PCR amplification was performed using the high fidelity DNA Polymerase PrimeSTAR HS DNA Polymerase kit in order to obtain a mutant-containing gene recombinant plasmid. The reaction system is shown in Table 2, and the PCR conditions are as follows: pre-denaturation: 4min at 95 ℃; denaturation: 10s at 98 ℃; annealing: 5s at 55 ℃; extension: 6min at 72 ℃; circulating for 25 times; fully extending: 10min at 72 ℃.
TABLE 1 primer Table
One round of PCR amplification was performed using the high fidelity DNA Polymerase PrimeSTAR HS DNA Polymerase kit in order to obtain a mutant-containing gene recombinant plasmid. The reaction system is shown in Table 2, and the PCR conditions are as follows: pre-denaturation: 4min at 95 ℃; denaturation: 10s at 98 ℃; annealing: 5s at 55 ℃; extension: 6min at 72 ℃; circulating for 25 times; fully extending: 10min at 72 ℃.
TABLE 2 reaction System for the first round of PCR amplification
Example 2: construction of multipoint creatine amidino hydrolase (BAA 88830.1) mutant
To further analyze the effect of different amino acid species at each site on the catalytic properties of the enzyme, the whole plasmid PCR technique was still used to obtain saturated mutant library genes, in reference to the site-directed mutagenesis method, as detailed below: PCR amplification was performed in multiple rounds using the high fidelity DNA Polymerase PrimeSTAR HS DNA Polymerase kit in order to obtain mutant-containing recombinant plasmids. The reaction system, PCR conditions and transformation conditions were the same as those of site-directed mutagenesis.
Example 3: construction of mutant engineering bacteria
The engineering bacteria are constructed by referring to the super competence kit instruction and slightly modifying, and the specific operation is as follows. First, it was confirmed that e.coli BL21 (DE 3) could not grow under Kan resistance; secondly, scribing, separating and activating the E.coli BL21 (DE 3); thirdly, taking a single colony, adding the single colony into an LB culture medium without resistance, and culturing the single colony to OD 600 Preparing competent cells from the solution of the kit between 0.5 and 0.6; fourthly, transforming and smearing the strain on an LB solid medium plate containing Kan resistance, and culturing for 14h; and finally, selecting 5 single colonies, carrying out PCR amplification on target genes by using a bacterial solution, identifying target bands by agarose gel electrophoresis, and selecting Jin Weizhi of Suzhou for sequencing to confirm the engineering bacteria.
Example 4: expression and purification of creatine amidino hydrolase mutant (BAA 88830.1) protein
Inoculating the engineering bacteria in the glycerin pipe to 100 mug/mL kanamycin (Kan) according to the volume ratio of 1 percent + ) In 4mL 2YT liquid medium test tube, at 3Culturing at 7 deg.C and 220rpm for 11 hr; then, the 4mL of the cell suspension was transferred to a cell suspension containing 50. Mu.g/mL kanamycin (Kan) + ) 2YT liquid medium 1L flask, at 37 degrees C, 220rpm under about 3h culture, to make OD600 to reach about 0.8; then 0.1mM IPTG inducer was added, and the mixture was subjected to induction culture at 25 ℃ and 200rpm for 11-17 hours, in this example for 14 hours. And (3) centrifuging the escherichia coli thallus suspension obtained after the induction expression, and performing one-step Ni-NTA affinity chromatography treatment to obtain the creatine amidino hydrolase protein with the purity of more than 95%.
Example 5: characterization of Properties of creatine amidinohydrolase mutant
The optimized wild-type creatine amidino hydrolase (BAA 88830.1) and the various creatine amidino hydrolase mutants provided by the embodiment 3 are subjected to a thermal stability test, and the method for determining the activity of the creatine amidino hydrolase specifically comprises the following steps:
the activity detection reaction of creatine amidinohydrolase is based on an enzyme coupling catalytic system, wherein creatine is catalyzed in the reaction system to generate sarcosine and urea, the sarcosine can react under the catalysis of Sarcosine Oxidase (SOX), and hydrogen peroxide (H) can be generated at the same time 2 O 2 ) Hydrogen peroxide can react with toss (N-ethyl-N- (2-hydroxy-3-sulfopropyl) m-toluidine sodium salt) and 4-AP (4-aminoantipyrine ) under the catalysis of horseradish peroxidase to produce purple compounds. Therefore, we evaluated the activity change of creatine amidinohydrolase, where activity is defined as the amount of enzyme that produces 1. Mu.M hydrogen peroxide per minute, by monitoring the amount of change in UV absorption at a wavelength of 555nm in a single enzymatic reaction system by a UV-2550 UV-visible spectrophotometer (Shimadzu).
The enzyme reaction system is as follows: 0.5mM TOOS (N-ethyl-N- (2-hydroxy-3-sulfopropyl) M-toluidine sodium salt), 0.45mM 4-AP (4-aminoantipyrine ), 900U/L horseradish peroxidase, 0.1M potassium phosphate buffer (pH 7.5).
1) The activity of creatine amidinohydrolase is measured by an enzyme multi-stage coupling method under the catalytic action of sarcosine oxidase and horseradish peroxidase, and a to-be-detected sample enzyme concentration is diluted to 1mg/ml by using a phosphate buffer solution (0.1M, pH 7.5). The substrate solution was prepared from 500. Mu.M creatine, 0.45mM 4-AA (4-aminoantipyrine), 0.5mM TOOS (N-ethyl-N- (2-hydroxy-3-sulfopropyl) -3-methylaniline) and phosphate buffer (0.1M, pH 7.5), and incubated at 37 ℃. The enzyme activity was measured by taking 950. Mu.L of the substrate solution and adding 50. Mu.L of the enzyme sample to be tested thereto, and the change in the absorption of ultraviolet light at 555nm in the enzyme reaction system was monitored by a UV2550 spectrophotometer (Shimadzu), and the unit activity was defined as the amount of the enzyme that generates 1. Mu.M hydrogen peroxide per minute.
2) The concentration of the purified enzyme was diluted to 1.0mg/mL in phosphate buffer (0.1M, pH 7.5) and incubated at 55 ℃ and 57 ℃ for various periods of time, 0min,5min,10min,15min,20min,30min, respectively, to perform an enzyme inactivation pre-experiment, and the half-life t of wild-type creatine amidino hydrolase (BAA 88830.1) was estimated 1/2 . Half-life calculation formula: t is t 1/2 K is the slope of a line plotting the natural log value of the remaining relative activity of the enzyme versus the time of heat treatment. The experimental results show that the thermal stability of the single-point mutant and the combined mutant is obviously improved, and the results are shown in table 3:
as shown in table 3, the creatine amidinohydrolase mutants provided by the present invention include single-site mutants and combinatorial mutants, and it was found by determining half-lives of wild-type creatine amidinohydrolase (BAA 88830.1) and creatine amidinohydrolase mutants at 57 ℃, that the thermal stabilities at 57 ℃ of the eight creatine amidinohydrolase mutants are significantly improved compared with optimized wild-type creatine amidinohydrolase (BAA 88830.1), and the eight creatine amidinohydrolase mutants are: T117P/T199S/T251C, F Y/T117P/T199S, T199S/D17V/K351E, L P/T117P/T199S, L6P/T117P/F108Y/T199S, L6P/D17V/T199S/T251C, L P/T117P/F108Y/T199S/T251C and L6P/T117P/T199S/T251C/K351E, with specific results as shown in Table 3.
TABLE 3 characterization of enzymatic Properties of wild-type creatine amidino hydrolase and its mutants
Although the present invention has been described with reference to the preferred embodiments, it should be understood that various changes and modifications can be made therein by those skilled in the art without departing from the spirit and scope of the invention as defined in the appended claims.
Claims (6)
1. A creatine amidinohydrolase mutant is characterized in that the creatine amidinohydrolase mutant is an L6P single-point mutant with an amino acid sequence shown in GenBank accession number BAA88830.1,
or any combination mutant of L6P/G58D, L6P/T117P, Q I/L6P/T117P, E V/L6P/T117P, L6P/T117P/T199S, L P/T117P/F108Y/T199S, L P/T117P/F108Y/G58D/T251C, L P/T117P/F108Y/T199S/T251C, L P/T117P/T199S/T251C/K351E.
2. A gene encoding the creatine amidinohydrolase mutant according to claim 1.
3. A recombinant plasmid comprising the gene of claim 2.
4. An immobilized or engineered bacterium comprising the creatine amidinohydrolase mutant according to any one of claims 1.
5. The engineered bacterium of claim 4, wherein said engineered bacterium comprises a fungal cell, a bacterial cell.
6. The engineered bacterium of claim 5, wherein said engineered bacterium comprises Escherichia coli, yeast or Bacillus subtilis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211447041.6A CN115851682A (en) | 2020-08-28 | 2020-08-28 | Creatine amidino hydrolase mutant with improved thermal stability |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010886832.3A CN112011528B (en) | 2020-08-28 | 2020-08-28 | Creatine amidino hydrolase mutant with improved thermal stability |
| CN202211447041.6A CN115851682A (en) | 2020-08-28 | 2020-08-28 | Creatine amidino hydrolase mutant with improved thermal stability |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010886832.3A Division CN112011528B (en) | 2020-08-28 | 2020-08-28 | Creatine amidino hydrolase mutant with improved thermal stability |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115851682A true CN115851682A (en) | 2023-03-28 |
Family
ID=73502396
Family Applications (10)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211447339.7A Pending CN116410966A (en) | 2020-08-28 | 2020-08-28 | Creatine amidinohydrolase mutant with improved heat stability |
| CN202010886832.3A Active CN112011528B (en) | 2020-08-28 | 2020-08-28 | Creatine amidino hydrolase mutant with improved thermal stability |
| CN202211447736.4A Pending CN116716281A (en) | 2020-08-28 | 2020-08-28 | Creatine amidinohydrolase mutant with improved heat stability |
| CN202211447324.0A Pending CN115786314A (en) | 2020-08-28 | 2020-08-28 | Creatine amidino hydrolase mutant with improved thermal stability |
| CN202211446967.3A Pending CN116716280A (en) | 2020-08-28 | 2020-08-28 | Creatine amidinohydrolase mutant with improved heat stability |
| CN202211446981.3A Pending CN116410965A (en) | 2020-08-28 | 2020-08-28 | Creatine amidinohydrolase mutant with improved heat stability |
| CN202211447041.6A Pending CN115851682A (en) | 2020-08-28 | 2020-08-28 | Creatine amidino hydrolase mutant with improved thermal stability |
| CN202211446983.2A Pending CN115806961A (en) | 2020-08-28 | 2020-08-28 | Creatine amidinohydrolase mutant with improved thermal stability |
| CN202211446969.2A Pending CN115896077A (en) | 2020-08-28 | 2020-08-28 | Creatine amidino hydrolase mutant with improved thermal stability |
| CN202211451065.9A Pending CN115975998A (en) | 2020-08-28 | 2020-08-28 | Creatine amidinohydrolase mutant with improved thermal stability |
Family Applications Before (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211447339.7A Pending CN116410966A (en) | 2020-08-28 | 2020-08-28 | Creatine amidinohydrolase mutant with improved heat stability |
| CN202010886832.3A Active CN112011528B (en) | 2020-08-28 | 2020-08-28 | Creatine amidino hydrolase mutant with improved thermal stability |
| CN202211447736.4A Pending CN116716281A (en) | 2020-08-28 | 2020-08-28 | Creatine amidinohydrolase mutant with improved heat stability |
| CN202211447324.0A Pending CN115786314A (en) | 2020-08-28 | 2020-08-28 | Creatine amidino hydrolase mutant with improved thermal stability |
| CN202211446967.3A Pending CN116716280A (en) | 2020-08-28 | 2020-08-28 | Creatine amidinohydrolase mutant with improved heat stability |
| CN202211446981.3A Pending CN116410965A (en) | 2020-08-28 | 2020-08-28 | Creatine amidinohydrolase mutant with improved heat stability |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211446983.2A Pending CN115806961A (en) | 2020-08-28 | 2020-08-28 | Creatine amidinohydrolase mutant with improved thermal stability |
| CN202211446969.2A Pending CN115896077A (en) | 2020-08-28 | 2020-08-28 | Creatine amidino hydrolase mutant with improved thermal stability |
| CN202211451065.9A Pending CN115975998A (en) | 2020-08-28 | 2020-08-28 | Creatine amidinohydrolase mutant with improved thermal stability |
Country Status (1)
| Country | Link |
|---|---|
| CN (10) | CN116410966A (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2404293C (en) * | 2001-09-20 | 2007-05-15 | F. Hoffmann-La Roche Ag | Variants of an erwinia-type creatinase |
| EP1298213A1 (en) * | 2001-09-20 | 2003-04-02 | Roche Diagnostics GmbH | Variants of an Erwinia-type creatinase |
| CN107257855B (en) * | 2015-02-27 | 2022-04-29 | 雷迪奥米特医学公司 | Modified creatinase |
-
2020
- 2020-08-28 CN CN202211447339.7A patent/CN116410966A/en active Pending
- 2020-08-28 CN CN202010886832.3A patent/CN112011528B/en active Active
- 2020-08-28 CN CN202211447736.4A patent/CN116716281A/en active Pending
- 2020-08-28 CN CN202211447324.0A patent/CN115786314A/en active Pending
- 2020-08-28 CN CN202211446967.3A patent/CN116716280A/en active Pending
- 2020-08-28 CN CN202211446981.3A patent/CN116410965A/en active Pending
- 2020-08-28 CN CN202211447041.6A patent/CN115851682A/en active Pending
- 2020-08-28 CN CN202211446983.2A patent/CN115806961A/en active Pending
- 2020-08-28 CN CN202211446969.2A patent/CN115896077A/en active Pending
- 2020-08-28 CN CN202211451065.9A patent/CN115975998A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN115896077A (en) | 2023-04-04 |
| CN115786314A (en) | 2023-03-14 |
| CN115806961A (en) | 2023-03-17 |
| CN116716281A (en) | 2023-09-08 |
| CN112011528B (en) | 2022-11-29 |
| CN116410965A (en) | 2023-07-11 |
| CN112011528A (en) | 2020-12-01 |
| CN116716280A (en) | 2023-09-08 |
| CN116410966A (en) | 2023-07-11 |
| CN115975998A (en) | 2023-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103103167B (en) | Mutant zymoprotein of D-amino acid oxidase and preparation method of mutant zymoprotein | |
| CN112831483B (en) | 5-amino-acetopropionic acid synthetase mutant and host cell and application thereof | |
| CN113430181B (en) | Bacterial laccase derived from Asian elephant intestinal metagenome and gene thereof | |
| CN110172454B (en) | S-adenosylmethionine synthetase mutant and high-throughput screening method thereof | |
| CN109370998B (en) | Omega-transaminase mutant I215F with improved catalytic efficiency | |
| KR102596402B1 (en) | HbA1c dehydrogenase | |
| CN113337495A (en) | Method for improving sialic acid yield and application | |
| CN110669751B (en) | Mutant zymoprotein of alanine racemase and preparation method thereof | |
| CN112011528B (en) | Creatine amidino hydrolase mutant with improved thermal stability | |
| CN108410845B (en) | D, D-carboxypeptidase DacA mutant with improved catalytic efficiency and preparation method thereof | |
| CN112011529B (en) | Creatine amidino hydrolase mutant with improved activity | |
| CN112226422B (en) | EstWY enzyme mutant with improved activity | |
| CN110938607A (en) | Glycerol-3-phosphate oxidase with good thermal stability and application thereof in kit | |
| CN115109770A (en) | Benzaldehyde lyase mutant and application thereof in preparation of 1, 4-dihydroxy-2-butanone | |
| CN111004794B (en) | Subtilisin E mutant with improved thermal stability and application thereof | |
| CN113151210B (en) | Peroxidase mutant with high specific enzyme activity and application thereof | |
| CN114621944B (en) | Arginine deiminase mutant with improved enzyme activity | |
| CN115927228B (en) | Mutant and construction method and application thereof | |
| CN113667651B (en) | NADH oxidase mutant with improved enzyme activity and changed optimal pH | |
| CN114058608B (en) | Engineering bacterium and method for producing putrescine | |
| CN109370997B (en) | Phenylalanine aminomutase mutant | |
| CN114317511B (en) | Protein, gene, recombinant vector, expression cassette, host and application | |
| CN113846082B (en) | Halohydrin dehalogenase mutant, encoding gene, recombinant vector, recombinant genetic engineering bacteria and application thereof | |
| CN109735511B (en) | Preparation method of xanthine oxidase for clinical detection | |
| CN110029094A (en) | A kind of sarcosine oxidase of mutation and its application in creatinine detection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |